Latest Innovation News

Bio-Gene Technology Limited has completed the second tranche of its share placement, securing approximately A$2.46 million and issuing unlisted options to investors and its lead manager.

InteliCare Holdings announces CEO Daniel Pilbrow’s resignation effective October 2025, with Non-Executive Director Tim Chapman stepping in as interim executive director during the leadership transition.

AML3D has secured a AU$1.2 million order from Austal USA for a portable ARCEMY Small additive manufacturing system, set to enhance the US Navy’s manufacturing capabilities with rapid deployment and flexible use.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.

AMP Limited reports a strong second quarter with Platforms net cashflows soaring 63.2% and Superannuation & Investments achieving positive net cashflows for the first time since 2017. AMP Bank remains steady amid ongoing innovation and market volatility.

Centrepoint Alliance has reported a robust FY25 with EBITDA rising 16% and net profit before tax jumping 30%, driven by strong adviser growth and strategic platform launches.

Equity Story Group has secured a transformative acquisition of Baker Young Limited, marking its entry into full-service wealth management and a major boost to its national footprint and recurring revenue.

Tryptamine Therapeutics has begun recruiting patients for a pioneering clinical trial testing IV-infused psilocin combined with psychotherapy to treat Binge Eating Disorder, aiming to deliver faster and more controlled treatment outcomes.

Omega Oil & Gas has secured a $7.3 million refundable R&D tax offset for FY23, bolstering its financial position and supporting ongoing development of its promising Canyon Project in Queensland.